



10th International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain
Preliminary Programme

Friday, 5 September 2025
Main Track | *Paranimf*

09:00 – 09:35	Welcome & Introduction Chairs: Anna Sureda (ES) & Alex Rampotas (UK) The EBMT: 2025 and beyond The Next-Gen: The EBMT Trainee Committee The EBMT Exam: Future Plans	Anna Sureda (ES) Alex Rampotas (UK) Isabel Sanchez-Ortega (ES)
09:35 – 10:45	Session I: Transplantation and Cellular Therapy: Fundamentals and Framework Chairs: Candice Hendricks (RSA) & John Snowden (UK) Hematopoietic cell transplantation: Why and How It Works? HLA System and donor selection CAR-T: The Game Changers <i>Case presentation:</i> Post-transplant Cyclophosphamide as GvHD prophylaxis in Matched Sibling Donor in patients with β -Thalassemia Major – A Single Centre Experience	John Snowden (UK) Neema Mayor (UK) Alberto Mussetti (ES) Reham Khalaf (EG)
10:30 – 10:40	<i>Case presentation:</i> Post-CART viral reactivations in paediatric patients: experience in a tertiary care centre	Alicia Pablos Lopez (ES)
10:40 – 10:45	Discussion and Q&A	
10:45 – 11:15	Coffee Break	
11:15 – 12:30	Session II: Transplant Science Chairs: Annalisa Ruggeri (IT) & Luca Vinci (DE) HSC Mobilization, Collection, Processing and Preservation Conditioning regimen and intensity Engraftment and Graft Dynamics <i>Case presentation:</i> Severe and fatal central nervous system toxicity after fludarabine, thiotepea and melphalan conditioning for allogeneic stem cell transplantation	Sara Vallejo Diez (ES) Florent Malard (FR) Annalisa Ruggeri (IT) Pleun Schonewille (NL)
12:10 – 12:30	Discussion and Q&A	
12:30 – 13:15	Lunch Break	
13:15 – 14:00	Industry Symposium by Therakos: “Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy”	
13:15 – 13:20	Introduction	
13:20 – 13:35	Prof Anna Sureda , Catalan Institute of Oncology, Duran I Reynals Hospital, Spain How to treat GvHD with ECP – current real-world management of GvHD in Spain	
13:35 – 13:50	Dr Guillermo Ortí , University Hospital Vall d’Hebron, Spain Evidence for treatment of chronic GvHD using ECP – a future backbone for GvHD therapy	
13:50 – 14:00	Dr Laura Fox , University Hospital Vall d’Hebron, Spain Discussion	

Friday, 5 September 2025
Main Track | *Paranimf*

14:00 – 15:30

Session III: GVHD

Chairs: *Mette Hazenberg (NL) & Fabio Ciceri (IT)*

14:00 – 14:15

GVHD Biology: What We Know So Far

Mette Hazenberg (NL)

14:15 – 14:30

Acute GVHD: Diagnosis, Prevention, and Treatment

Zinaida Peric (HR)

14:30 – 14:45

The Forgotten Site: Stomach GVHD in Allogeneic Stem Cell Transplantation

Jana Gawron (DE)

14:45 – 14:55

Case presentation:

Effective treatment with Mesenchymal Stromal Cells for refractory Graft-Versus-Host

Disease after allo-HCT complicated by BK virus-associated haemorrhagic cystitis in a patient with AML

Maddalena V. Ponti (IT)

14:55 – 15:05

Case presentation:

Hyperbilirubinemia in the 5th Month Post-Allogeneic Transplantation

Marina Herrero (ES)

15:05 – 15:30

Discussion and Q&A

15:30 – 16:00

Coffee Break

16:00 – 17:15

Session IV: Late Complications, Ethics and Patient Perspectives

Chairs: *Carmelo Gurnari (IT) & Giorgio Orofino (IT)*

16:00 – 16:15

Late Complications after transplantation

Michelle Kenyon (UK)

16:15 – 16:30

Effective Communication for Transplant and CT Physicians

Carmelo Gurnari (IT)

16:30 – 16:40

CAR-T survivorship

Anna Barata (US)

16:40 – 16:50

Patient and caregiver outcomes after CAR-T therapy

David Aguilar Prieto (ES)

16:50 – 17:00

Case presentation:

Late cytopenia post-CAR T-cell infusion and clonal haematopoiesis: a case report Desirée Eboli (IT)

17:00 – 17:15

Discussion and Q&A

17:15 – 18:00

Keynote Lecture

Chair: *Alex Rampotas (UK)*

Endothelia and early complications after HCT

Enric Carreras (ES)

18:00 – 18:45

Poster Session

Further details about the poster presenters can be found on the next page.

Friday, 5 September 2025
Poster Session | Foyer

18:00 – 18:45

Poster Session

Moderators: Annalisa Ruggeri (IT)

Poster 1	Cutaneous chronic graft-versus-host disease mimicking acanthosis nigricans	Lucas Anastacio (BR)
Poster 2	Early CMV, Adenovirus, BKV and HHV-6 coinfection following allogeneic Hematopoietic stem cell transplantation: diagnostic and therapeutic barriers in a developing country	Lucas Anastacio (BR)
Poster 3	An unexpected guest: cerebral toxoplasmosis in a paediatric patient after Hematopoietic stem cell transplantation	Miriam Cañada (ES)
Poster 4	Experience with maribavir in resistant/ refractory cytomegalovirus (cmv) infection in paediatric stem cell transplant recipients	Laia Garcia (ES)
Poster 5	Extensive ileitis in early phase after allogeneic hematopoietic stem cell transplantation	Irene Gorostidi (ES)
Poster 6	Long-Term Dual Remission of Therapy-Related AML and Multiple Myeloma Using Stored Autologous Stem Cells and Haploidentical Transplant	Yashashree Gupta
Poster 7	Three Transplants and Beyond: A Complex Case of Hypoplastic MDS with Rare HLA Haplotype, Graft Failures, and EBV-Driven CNS Lymphomatoid Granulomatosis	Shreyas Hanmantgad (UK)
Poster 8	A complex case of chronic GVHD presenting with serositis	Josephine Lucero (CA)
Poster 9	Immunologic predictive factors for CMV reactivation in SR-cGVHD patients treated with ruxolitinib	Leonardo Maia (PT)
Poster 10	Machine Learning-Based Prediction of Functional Recovery in Spinal Cord Injury Patients Undergoing Autologous Mesenchymal Stem Cell Transplantation: A Retrospective Study from East Java	Bidayatul Masulah (NL)
Poster 11	The Reveal of the Aetiology of Secondary Myelofibrosis by a Unique Post Transplant Complication	Dina Osman (UK)
Poster 12	Toxic Epidermal Necrolysis Mimicking Severe Cutaneous aGVHD Post Allogeneic HSCT: A Diagnostic Challenge	Titas Tiskevicius (LT)

09:00 – 11:00	Session V: Indications for allogeneic HCT in Adults Chairs: Donal McLornan (UK) & Moniek de Witte (NL)	
09:00 – 09:30	Introductory Case-based: Indications of HCT in AML Indications of HCT in AML	Fanny Palumbo (IT) Fabio Ciceri (IT)
09:30 – 10:00	Introductory Case-based: Indications of HCT in MDS Indications of HCT in MDS	Piotr Kacprzyk (PL) Joanna Drozd-Sokołowska (PL)
10:00 – 10:30	Introductory Case-based: Indications of HCT in MPN Indications of HCT in MPN	Yousif Hameed (UK) Donal McLornan (UK)
10:30 – 11:00	Introductory Case-based: Indications of HCT in Bone marrow failures Indications of HCT in Bone marrow failures	Jamie Macleod (UK) José Cilleruelo (UK)
11:00 – 11:30	Coffee Break	
11:30 – 13:00	Session VI: Transforming Care: HCT and CAR-T Therapies Chairs: Raffaella Greco (IT) & Sebastian Giebel (PL)	
11:30 – 11:45	Indications of HCT in ALL	Sebastian Giebel (PL)
11:45 – 12:00	CAR-T for ALL	Mike Northend (UK)
12:00 – 12:15	CAR-T for Myelofibrosis	Alex Rampotas (UK)
12:15 – 12:30	The alternative HCT: Autoimmune diseases	Tobias Alexander (DE)
12:30 – 12:45	Emerging CAR-T Indications in Autoimmune diseases	Raffaella Greco (IT)
12:45 – 13:00	Discussion and Q&A	
13:00 – 14:00	Lunch Break	
14:00 – 15:15	Session VII: Lymphoma: Bridging Transplant and CAR-T Therapies Chairs: Anna Sureda (ES) & Alex Rampotas (UK)	
14:00 – 14:15	Indications of HCT in Lymphoma	Ali Bazarbachi (LB)
14:15 – 14:30	CAR-T for Lymphoma	Anna Sureda (ES)
14:30 – 14:45	CAR-T Complications	
14:45 – 14:55	<i>Case Presentation:</i> Cyclosporine-Associated Central Pontine Myelinolysis Presenting as Peduncular Hallucinoses Following Allogeneic Hematopoietic Stem Cell Transplantation	Camila Donadel (BR)
14:55 – 15:05	<i>Case Presentation:</i> Hepatic Graft-versus-Host Disease Following Brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma after Allogeneic Transplantation	Elena Bechtold (ES)
15:05 – 15:15	Discussion and Q&A	
15:15 – 15:45	Coffee Break	



10th International Transplant and Cellular Therapy Course

5-7 September 2025 | Barcelona, Spain
Preliminary Programme

Saturday, 6 September 2025
Main Track | *Paranimf*

15:45 – 17:00

Session VIII: Advances and Challenges in Multiple Myeloma

Chairs: Adrian Mosquera Orgueira (ES) & Luis Gerardo Rodríguez-Lobato (ES)

15:45 – 16:00

Indications of HCT in Multiple Myeloma

Patrick Hayden (IE)

16:00 – 16:15

CAR-T for Multiple Myeloma

Luis Gerardo Rodríguez-Lobato (ES)

16:15 – 16:30

Strategies to Overcome Challenges in CAR-T Cell Therapy

Carlos Fernández De Larrea (ES)

16:30 – 16:40

Case presentation:

Daratumumab as a Novel Therapeutic Option for Refractory Pure Red Cell Aplasia

Following Major ABO-Incompatible Allogeneic HSCT

Nevena Besevic (RS)

16:40 – 17:00

Discussion and Q&A

17:00 – 17:45

Keynote Lecture

Chair: Annalisa Ruggeri (IT)

Modulation of the microbiota in haematology: current status and perspectives

Mohamad Mohty (FR)

09:00 – 11:00	Session I: Preparation, cell collection, conditioning and infusion Chairs: Michelle Kenyon (UK) & Hilda Mekelenkamp (NL)	
09:00 – 09:10	Welcome & Introduction	Hilda Mekelenkamp (NL)
09:10 – 09:30	Right donor, right patient, right time	Annika Kisch (SE)
09:30 – 09:55	Preparing for transplant: all you need to know	Davide Bonomi (IT)
09:55 – 10:15	Conditioning regimens different approaches and why	Marijke Quaghebeur (BE)
10:15 – 10:40	Cell infusion: stem cell, CART and lymphocytes: exploring the differences	Sandrine Bremathas (UK)
10:40 – 11:00	CVCs - evidencing best practice	Solveig Adalsteinsdóttir (SE)
11:00 – 11:30	Coffee Break	
11:30 – 13:00	Session II: Post infusion care Chairs: Claudia Boglione (IT) & Marijke Quaghebeur (BE)	
11:30 – 11:50	Nutritional support – the current guidance	Katie Ahern (IE)
11:50 – 12:15	Infections and keeping our patients safe	Thomas Jézéquel (FR)
12:15 – 12:45	Early complications	Anna Serrahima (ES)
12:45 – 13:00	How to write an abstract	Hilda Mekelenkamp (NL)
13:00 – 14:00	Lunch Break	
14:00 – 15:15	Session III: Transplant complications Chairs: Thomas Jézéquel (FR) & Anna Serrahima (ES)	
14:00 – 14:15	Acute GvHD & graft management	Silvia Gnechi (IT)
14:15 – 14:30	cGvHD	John Murray (UK)
14:30 – 14:35	GvHD Q&A	
14:35 – 14:55	Conception, sex and sexuality	Iebe de Quick (BE)
14:55 – 15:15	Long term follow-up, QoL, and survivorship	Michelle Kenyon (UK)
15:15 – 15:45	Coffee Break	
15:45 – 16:30	Session IV: Essential update Chairs: Hilda Mekelenkamp (NL) & Annika Kisch (SE)	
15:45 – 16:05	Paediatric update	Hilda Mekelenkamp (NL)
16:05 – 16:25	Evolving treatments in auto-immune disease	Claudia Boglione (IT)
16:25 – 16:30	Closing remarks	Hilda Mekelenkamp (NL)
17:00 – 17:45	Keynote Lecture (Paranimf) Chair: Annalisa Ruggeri (IT) Modulation of the microbiota in haematology: current status and perspectives	Mohamad Mohty (FR)

09:00 – 11:00

Session I: Leukemias in children (PDWP)

Chairs: Krzysztof Kałwak (PL) & Benedetta E. Di Majo (IT)

09:00 – 09:25

Paediatric ALL TBI vs non-TBI

09:25 – 09:50

CAR-T cells in B-ALL

09:50 – 10:15

AML in 2025: Who and when to transplant?

10:15 – 10:40

CML: is there still a role for transplant in the era of TKIs?

10:40 – 10:50

Case Presentation:

Beyond remission: Uncertainties in Late-Onset Hepatic complications after CAR-T therapy and hematopoietic stem cell transplantation

Krzysztof Kałwak (PL)

Giovanna Lucchini (IT)

Dominik Turkiewicz (SE)

Herbert Pichler (AT)

José Antonio Flores (ES)

10:50 – 11:00

Discussion

11:00 – 11:30

Coffee Break

11:30 – 13:00

Session II: HSCT and Gene therapy in PIDS and metabolic disorders (IEWP)

Chairs: Maria Ester Bernardo (IT) & Anna-Lisa Lanz (DE)

11:30 – 11:45

Indications to allo-HSCT vs. HSC-GT in LSDs

Maria Ester Bernardo (IT)

11:45 – 12:10

Indications to allo-HSCT vs. HSC-GT in PIDs

Claire Booth (UK)

12:10 – 12:45

Which haploidentical platform to be employed in PID patients (TCR ab vs. pCY)?

Bénédicte Neven (FR)

12:45 – 13:00

Discussion

13:00 – 14:00

Lunch Break

14:00 – 15:15

Session III: From Fanconi Anemia + MDS. (SAAWP + MDS-EWOG)

Chairs: Luca Vinci (DE) & Su Han Lum (UK)

14:00 – 14:25

HSCT in Fanconi Anaemia

Su Han Lum (UK)

14:25 – 14:50

HSCT in MDS/JMML

Luca Vinci (DE)

14:50 – 15:00

Case Presentation:

A severe cutaneous graft-versus-host disease reaction in the setting of herpes simplex virus-1 infection and tissue repair deficiency

Paula Mazorra Roig (ES)

15:00 – 15:15

Discussion

15:15 – 15:45

Coffee Break

15:45 – 16:55

Session IV: HSCT vs Gene therapy in hemoglobinopathies (HWP)

Chairs: Josu de la Fuente (UK) & Esraa Khalil (OM)

15:45 – 16:10

HSCT and gene therapy in sickle cell disease

Josu de la Fuente (UK)

16:10 – 16:40

HSCT and gene therapy in thalassaemia

Mattia Algeri (IT)

16:40 – 16:50

Case Presentation

First experience of allogeneic hematopoietic stem cell transplantation for sickle cell disease patients in a low resource country (Tanzania)

Catherine Mhando (TZ)

16:50 – 17:00

Case Presentation

Cerebral infarcts associated with micro embolic phenomena in the setting of infective endocarditis after allogeneic hematopoietic stem cell transplantation for sickle cell disease

Lucas Anastacio (BR)

17:00 – 17:45

Keynote Lecture (Paranimf)

Chair: Annalisa Ruggeri (IT)

Modulation of the microbiota in haematology: current status and perspectives

Mohamad Mohty (FR)

09:00 – 10:00	Session IX: Complications after HCT	
	Chairs: Isabel Sanchez - Ortega (ES) & Ibrahim Yakoub-Agha (FR)	
09:00 – 09:15	Early Endothelial Complications	Ibrahim Yakoub-Agha (FR)
09:15 – 09:25	Neurological complications	Giorgio Orofino (IT)
09:25 – 09:40	Improving infectious complications	José Luis Piñana (ES)
09:40 – 09:50	<i>Case Presentation:</i>	
	Refractory post-transplant associated thrombotic microangiopathy in an adult patient with severe aplastic anaemia: exploring diagnostic and therapeutic challenges	Andrea Lattanzi (IT)
09:50 – 10:00	<i>Case Presentation:</i>	
	Haemophagocytic Lymphohistiocytosis and EBV reactivation in severe Systemic Sclerosis after Autologous Transplant	Maria Chiara Auriemma (IT)
10:00 – 11:15	Session X: Optimizing Outcomes in Relapse Management	
	Chairs: Yousif Hameed (UK) & Jürgen Kuball (NL)	
10:00 – 10:15	Immune Escape in Relapse	Cristina Toffalori (IT)
10:15 – 10:30	Role of DLI to improve outcomes	Jürgen Kuball (NL)
10:30 – 10:45	Graft manipulation for better outcomes	Peter Lang (DE)
10:45 – 10:55	<i>Case Presentation:</i>	
	Management of Post-Transplant Relapse in a Young Adult Patient with Acute Myeloid Leukaemia: A Clinical Case	Alessandro Criscimanna (IT)
10:55 – 11:05	<i>Case Presentation:</i>	
	Durable Remission with Glofitamab Post- HSCT in a Patient with Relapsed/Refractory Burkitt Lymphoma with CNS Involvement	Yashashree Gupta (UK)
11:05 – 11:15	<i>Case Presentation:</i>	
	CC-486 as a Bridge to Allogeneic Transplantation in TP53-Mutated MDS del(5q): A Case Report and Reflection on GvHD Management in the Elderly	Anna Francesio (IT)
11:15 – 11:45	Coffee Break	
11:45 – 12:45	Session XI: Next-Generation Strategies in HCT and CAR-T	
	Chairs: Nicolaus Kröger (DE) & Alberto Mussetti (ES)	
11:45 – 12:00	Measurable residual disease	Nicolaus Kröger (DE)
12:00 – 12:15	Using Machine Learning and AI in HCT and CAR-T	Adrian Mosquera Orgueira (ES)
12:15 – 12:30	What's next in cellular therapy?	Moniek de Witte (NL)
12:30 – 12:40	<i>Case Presentation:</i>	
	Donor-derived CD45RA ⁺ T-Cell infusion for disseminated Adenovirus infection following haploidentical HSCT in a pediatric patient with CAEBV and Hodgkin Lymphoma	Francesca Ciritella (IT)
12:40 – 12:45	Discussion and Q&A	
12:45 – 13:00	Poster awards and Closing Remarks	
	Chairs: Anna Sureda (ES)	